Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Hyperparathyroidism and its management]

T Sugimoto1

  • 1Department of Medicine, Kobe University School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|July 2, 1998
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Molecular cloning and characterization of the platelet-activating factor receptor gene expressed in the human heart.

Biochemical and biophysical research communications·1992
Same author

Reappraisal of the coupling interval of ventricular extrasystoles as an index of ectopic mechanisms.

British heart journal·1992
Same author

Effects of manidipine hydrochloride on the renal microcirculation in spontaneously hypertensive rats.

Journal of cardiovascular pharmacology·1992
Same author

Calretinin-immunoreactivity in the oro-facial and pharyngeal regions of the rat.

Neuroscience letters·1992
Same author

Cellular mechanisms for synthesis and secretion of atrial natriuretic peptide and brain natriuretic peptide in cultured rat atrial cells.

Circulation research·1992
Same author

Expression and role of interleukin-2 receptor beta chain on CD4-CD8- T cell receptor alpha beta+ cells [corrected].

European journal of immunology·1992
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Hyperparathyroidism (HPT) causes secondary osteoporosis. Treatments vary by HPT type: parathyroidectomy for primary HPT, and dietary changes or vitamin D for secondary HPT due to chronic renal failure.

Area of Science:

  • Endocrinology
  • Nephrology
  • Bone Metabolism

Context:

  • Hyperparathyroidism (HPT), characterized by excess parathyroid hormone, is a significant cause of secondary osteoporosis.
  • HPT is classified into primary (1°) and secondary (2°) forms, with 2° HPT often linked to chronic renal failure (CRF).
  • Biochemical markers differentiate HPT-induced osteoporosis from primary osteoporosis.

Purpose:

  • To outline the distinct causes and management strategies for primary and secondary hyperparathyroidism.
  • To highlight the effectiveness of parathyroidectomy in treating primary HPT and its impact on bone mass.
  • To review therapeutic options for secondary HPT in chronic renal failure, including medical management and interventional procedures.

Summary:

  • Primary HPT is radically cured by parathyroidectomy (PTX), leading to over a 10% increase in bone mass.

Related Experiment Videos

  • Secondary HPT due to CRF is managed with dietary phosphorus restriction, phosphorus binders, and active vitamin D3 metabolites.
  • When medical therapies fail for secondary HPT, options include oral active vitamin D3 pulse therapy, PTX, and percutaneous ethanol injection therapy.

    • Impact:

    • Provides a clear distinction between primary and secondary HPT management.
    • Emphasizes the significant bone recovery potential following PTX for primary HPT.
    • Offers a comprehensive overview of treatment algorithms for HPT-related bone disease in CRF patients.